

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the month of October 2022**

Commission File Number: **001-39458**

**Medicenna Therapeutics Corp.**  
(Translation of registrant's name into English)

**2 Bloor St. W., 7th Floor**  
**Toronto, Ontario M4W 3E2, Canada**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**MEDICENNA THERAPEUTICS CORP.**

Date: October 5, 2022

By: /s/ Elizabeth Williams  
Name: Elizabeth Williams  
Title: Chief Financial Officer

---

## EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press Release dated October 5, 2022</a>

## Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37<sup>th</sup> Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below.

**Title:** Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting ‘Beta-only’ IL2 Agonist

**Abstract Number:** 743

**Poster Presentation Date and Time:** November 10, 2022, from 9:00 a.m. – 9:00 p.m. ET

**Poster Session Location:** Boston Convention and Exhibition Center, Hall C

**Title:** Interim Single-agent Safety and Anti-tumor Activity from Dose Escalation Phase of ABILITY Study on MDNA11, a Long-acting Beta-only IL-2 Agonist

**Abstract Number:** 744

**Poster Presentation Date and Time:** November 11, 2022, from 9:00 a.m. – 8:30 p.m. ET

**Poster Session Location:** Boston Convention and Exhibition Center, Hall C

### About Medicenna

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna's early-stage BiSKITs™ program, (**B**ifunctional **S**uper**K**ine **I**mmuno**T**herapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

### Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com

### Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com